IMU

0.00%

4.8¢ imugene limited

"In my experience I have not seen too many posters sessions...

First 60 Last

Share
Profile

Follow
SENARIS

2,923 Posts.

132

28/01/23

10:34

Post #: 65921384
Share

Originally posted by Outlander2: ↑

Hi Ragnarolf

Thank you for sharing the feedback from the IMU team.

You ask about the upcoming NextHerizon 'trial in progress' poster session.
As we know the NextHerizon trial is exploring the impact of HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2+ gastric cancer. It is of course, an ongoing trial.
I posted, some time ago, regarding the different types of sessions that are usually available in a conference setting. I have attended numerous conferences, and in doing so, have attended many poster sessions. Most are there to report the the latest (often almost complete) data. Having said that, I would hope for a full oral presentation, if the trial was indeed complete, with the data fully unpacked.
It is not uncommon though, for a poster session to be offered that provides the data on 'what they are currently seeing'. To me, this could be a good opportunity to give interested researchers, and Big Pharma, a closer look at how the trial is tracking.
In my experience I have not seen too many posters sessions where they are releasing data that is 'less than good', if you know what I mean.

As for the 'merging' of the NeuHERIZON trial into the NeoHERIZON, or in their words ... "building into the study" it is probably an economic decision as much as anything else. Good to know though, that NeoHERIZON now has a trial leader, who I assume will be announced shortly.

Again, thanks for sharing. It looks to be all solid and positive to me. I believe HER-Vaxx will soon be a standout in this field, especially when used in combo existing FDA approved treatments. It is clearly safe, effective and cheaper.

My opinions only of course.

Expand

"In my experience I have not seen too many posters sessions where they are releasing data that is 'less than good', if you know what I mean."

good point

IMU Price at posting: 14.5¢ Sentiment: None Disclosure: Held
9 Upvote

1 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

There are more pages in this discussion • 4 more messages in this thread...

First 60 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.000(0.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
4.9¢	4.9¢	4.8¢	$328.5K	6.792M

Buyers (Bids)

No.	Vol.	Price($)
45	5443565	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	2171910	5

View Market Depth

No.	Vol.	Price($)
36	4613688	0.048
36	4066646	0.047
46	3070983	0.046
60	6170008	0.045
11	1951364	0.044

Price($)	Vol.	No.
0.049	1200533	2
0.050	4130537	15
0.051	6179811	13
0.052	2579418	10
0.053	1158504	8

Last trade - 16.10pm 04/10/2024 (20 minute delay)

IMU (ASX) Chart

"In my experience I have not seen too many posters sessions...

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

"In my experience I have not seen too many posters sessions...

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News